HUP0301465A3 - Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition - Google Patents
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the compositionInfo
- Publication number
- HUP0301465A3 HUP0301465A3 HU0301465A HUP0301465A HUP0301465A3 HU P0301465 A3 HUP0301465 A3 HU P0301465A3 HU 0301465 A HU0301465 A HU 0301465A HU P0301465 A HUP0301465 A HU P0301465A HU P0301465 A3 HUP0301465 A3 HU P0301465A3
- Authority
- HU
- Hungary
- Prior art keywords
- composition
- dosage forms
- therapeutic agents
- controlled release
- forms including
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- 238000013270 controlled release Methods 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000002496 gastric effect Effects 0.000 title 1
- 230000014759 maintenance of location Effects 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Manufacturing & Machinery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21383200P | 2000-06-23 | 2000-06-23 | |
US21711000P | 2000-07-10 | 2000-07-10 | |
US22321200P | 2000-08-04 | 2000-08-04 | |
PCT/US2001/020134 WO2002000213A1 (en) | 2000-06-23 | 2001-06-22 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0301465A2 HUP0301465A2 (hu) | 2004-05-28 |
HUP0301465A3 true HUP0301465A3 (en) | 2006-07-28 |
Family
ID=27395915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0301465A HUP0301465A3 (en) | 2000-06-23 | 2001-06-22 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1305021A4 (es) |
JP (1) | JP2004501190A (es) |
KR (1) | KR20030013460A (es) |
AU (2) | AU2001268722B8 (es) |
CA (1) | CA2412490A1 (es) |
CZ (1) | CZ2003199A3 (es) |
EA (1) | EA200300046A1 (es) |
HU (1) | HUP0301465A3 (es) |
IL (1) | IL153497A0 (es) |
MX (1) | MXPA02012793A (es) |
WO (1) | WO2002000213A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608640B2 (en) | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
IL160363A0 (en) * | 2001-08-16 | 2004-07-25 | Oregon State | Expandable gastric retention device |
BE1015608A6 (fr) | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
EP1615632B1 (fr) * | 2003-04-17 | 2006-12-06 | Jallal Messadek | Formulations orales flottantes pour la liberation controlee de la betaine |
US20050113452A1 (en) * | 2003-10-20 | 2005-05-26 | Moshe Flashner-Barak | Composition and dosage form for sustained effect of levodopa |
JP2005132803A (ja) * | 2003-10-31 | 2005-05-26 | Ono Pharmaceut Co Ltd | 胃内滞留固形剤 |
TW200533391A (en) * | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
FR2874325B1 (fr) * | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
WO2006050581A2 (en) | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
WO2006086856A1 (en) | 2005-02-15 | 2006-08-24 | Messadek, Jallal | Combination therapeutic compositions and method of use |
MX2007013486A (es) | 2005-04-27 | 2008-03-14 | Jallal Messadek | Combinaciones de insulinas. |
NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
UA95954C2 (ru) * | 2006-05-31 | 2011-09-26 | Солвей Фармасьютикалс Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
EP1872775A1 (en) * | 2006-06-29 | 2008-01-02 | Polichem S.A. | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
CL2007002574A1 (es) * | 2006-09-08 | 2008-05-23 | Drug Tech Corp Sa Organizada B | Composicion farmaceutica oral que comprende levodopa en una dosis unitaria de alrededor de 100 hasta alrededor de 500 mg y un excipiente adecuado; y su uso para tratar parkinson. |
WO2008039186A2 (en) * | 2006-09-26 | 2008-04-03 | Plensat, Llc | Method and system for treatment of eating disorders |
CA2673485A1 (en) | 2007-01-15 | 2008-07-24 | Kissei Pharmaceutical Co., Ltd. | Gastric retention-type sustained-release levodopa preparation |
KR20080076382A (ko) * | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
DE102007026037A1 (de) * | 2007-06-04 | 2008-12-11 | Lts Lohmann Therapie-Systeme Ag | Gastroretentives System mit Alginat-Körper |
CA2694602A1 (en) * | 2007-07-27 | 2009-02-05 | Depomed, Inc. | Pulsatile gastric retentive dosage forms |
CN102076215A (zh) | 2008-06-30 | 2011-05-25 | 托卡根公司 | 5-氟胞嘧啶制剂及其用途 |
AU2009281752B2 (en) | 2008-08-15 | 2016-11-17 | Depomed Inc. | Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders |
CA2742680C (en) * | 2008-11-07 | 2013-12-31 | Samyang Corporation | Pharmaceutical compositions for release control of methylphenidate |
WO2012093974A1 (en) * | 2011-01-06 | 2012-07-12 | Mahmut Bilgic | Improved bisphosphonate formulations |
CN103385871B (zh) * | 2012-05-07 | 2017-06-23 | 新疆医科大学 | 复方左旋多巴微囊漂浮片 |
WO2013183058A2 (en) | 2012-06-07 | 2013-12-12 | Tulip Medical Ltd. | Expanded device |
WO2014174388A1 (en) * | 2013-03-29 | 2014-10-30 | Wockhardt Limited | Modified release pharmaceutical compositions of methylphenidate or salts thereof |
JP6204141B2 (ja) * | 2013-04-22 | 2017-09-27 | テイカ製薬株式会社 | 口腔内速崩壊性固形製剤用組成物 |
US10994013B2 (en) | 2013-04-24 | 2021-05-04 | Temple University—Of the Commonwealth System of Higher Education | Solid dosage form containing arabinogalactan |
US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
CA2926082C (en) | 2013-10-07 | 2022-06-14 | Impax Laboratories, Inc. | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
WO2015083171A1 (en) * | 2013-12-05 | 2015-06-11 | Tulip Medical Ltd. | Retentive devices and systems for in-situ release of pharmaceutical active agents |
AU2016225052B2 (en) * | 2015-02-27 | 2021-07-08 | Cingulate Therapeutics LLC | Tripulse release stimulant formulations |
JP6823539B2 (ja) * | 2017-05-26 | 2021-02-03 | 株式会社ファンケル | 胃内滞留性錠剤 |
US10987311B2 (en) | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
US10588863B2 (en) | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
ES2928071T3 (es) | 2017-06-16 | 2022-11-15 | Amneal Complex Products Res Llc | Formas de dosificación gastrorretentiva para el suministro sostenido de fármacos |
JP7048770B2 (ja) | 2018-06-18 | 2022-04-05 | アムニール コンプレックス プロダクツ リサーチ エルエルシー | ピリドスチグミンを含む持続放出組成物 |
DK3628004T3 (da) | 2018-06-27 | 2021-12-20 | Amneal Complex Products Res Llc | Selvregulerende osmotiske mave-tarm tilbageholdende leveringssystemer til lægemiddel |
JP7044649B2 (ja) * | 2018-06-28 | 2022-03-30 | 株式会社ファンケル | 胃内浮遊錠剤 |
WO2020230089A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
WO2021176360A1 (en) * | 2020-03-02 | 2021-09-10 | Craft Health Pte Ltd | Oral dosage forms for extended drug release |
US11571402B2 (en) * | 2021-02-17 | 2023-02-07 | Springworks Therapeutics, Inc. | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
AU8578498A (en) * | 1997-07-23 | 1999-02-16 | Perio Products Ltd. | Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
-
2001
- 2001-06-22 AU AU2001268722A patent/AU2001268722B8/en not_active Ceased
- 2001-06-22 AU AU6872201A patent/AU6872201A/xx active Pending
- 2001-06-22 WO PCT/US2001/020134 patent/WO2002000213A1/en active IP Right Grant
- 2001-06-22 MX MXPA02012793A patent/MXPA02012793A/es not_active Application Discontinuation
- 2001-06-22 KR KR1020027017538A patent/KR20030013460A/ko not_active Application Discontinuation
- 2001-06-22 CZ CZ2003199A patent/CZ2003199A3/cs unknown
- 2001-06-22 HU HU0301465A patent/HUP0301465A3/hu unknown
- 2001-06-22 JP JP2002504995A patent/JP2004501190A/ja active Pending
- 2001-06-22 EA EA200300046A patent/EA200300046A1/ru unknown
- 2001-06-22 IL IL15349701A patent/IL153497A0/xx unknown
- 2001-06-22 CA CA002412490A patent/CA2412490A1/en not_active Abandoned
- 2001-06-22 EP EP01946709A patent/EP1305021A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1305021A1 (en) | 2003-05-02 |
EP1305021A4 (en) | 2009-09-23 |
KR20030013460A (ko) | 2003-02-14 |
MXPA02012793A (es) | 2004-07-30 |
HUP0301465A2 (hu) | 2004-05-28 |
WO2002000213A1 (en) | 2002-01-03 |
AU6872201A (en) | 2002-01-08 |
EA200300046A1 (ru) | 2003-10-30 |
CA2412490A1 (en) | 2002-01-03 |
AU2001268722B8 (en) | 2005-09-29 |
AU2001268722B2 (en) | 2005-08-11 |
IL153497A0 (en) | 2003-07-06 |
CZ2003199A3 (cs) | 2003-12-17 |
JP2004501190A (ja) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0301465A3 (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
HK1060305A1 (en) | Contraception process and administration form for the same | |
HUP0301325A3 (en) | Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition | |
MXPA03003895A (es) | Formulaciones de hidrocodona de liberacion controlada. | |
HUP0301242A3 (en) | Controlled release drug dosage form | |
AU2001253479A1 (en) | Targeted therapeutic agent release devices and methods of making and using the same | |
IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
AU2001280597A1 (en) | Compositions for sustained release of analgesic agents, and methods of making and using the same | |
MXPA02004770A (es) | Composiciones terapeuticas y metodos para su uso. | |
IL153708A0 (en) | Benzimidazole derivatives, preparation and therapeutic use thereof | |
IL151890A0 (en) | Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain | |
EP1257255A4 (en) | THERAPEUTIC PRODUCT, ITS USE AND MANUFACTURE | |
AU2002360717A1 (en) | Controlled release dosage form having improved drug release properties | |
GB0002386D0 (en) | Therapeutic composition | |
FI20000780A (fi) | Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi | |
MXPA03004303A (es) | DERIVADOS SUSTITUIDOS DE ACIDO AMINO-FURAN-2-IL-ACETICO Y ACIDO AMINO-TIEN-2-IL-ACETICO Y SU USO PARA EL TRATAMIENTO DE MIGRAnA Y DOLOR. | |
EP1501352A4 (en) | METHOD AND COMPOSITIONS FOR PROTRACTED ACTIVE SUBSTANCE | |
IL151765A0 (en) | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain | |
IL151891A0 (en) | Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain | |
HUP0102159A3 (en) | Pharmaceutical composition for the treatment of rumen acidosis | |
HUP0204417A3 (en) | Oral ciprofloxacin-composition of controlled release | |
GB0030067D0 (en) | Therapeutic agent | |
EP1357898A4 (en) | ORAL DOSAGE FORM WITH ENHANCED REGULATED RELEASE | |
HK1046848A1 (en) | Specific therapeutic composition for treating aids | |
HK1055954A1 (en) | Crystalline therapeutic agent. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |